**Potential targets for CAR-T therapy in acute myeloid leukemia (AML)**

**Chimeric antigen receptor (CAR) T cell**

**AML blast**

---

**Advantages**

<table>
<thead>
<tr>
<th>CD33</th>
<th>Ubiquitous on AML blasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD123</td>
<td>Ubiquitous on AML blasts</td>
</tr>
</tbody>
</table>

**Disadvantages**

- Present on normal HSPC → hematopoietic toxicity
- Limited published data
- Present on normal HSPC → hematopoietic toxicity
- Require a rescue allogeneic stem cell transplant (alloHSCT)
- Present on the endothelium of small-calibre blood vessels → vascular leak
- Many different types of cellular stress can upregulate NKG2D ligands on normal tissues → reduced specificity of NKG2D-CARs for malignant tissues

_Cummins and Gill. Haematologica, 2019_